CA3121270A1 - Novel approach for treatment of cancer using immunomodulation - Google Patents

Novel approach for treatment of cancer using immunomodulation Download PDF

Info

Publication number
CA3121270A1
CA3121270A1 CA3121270A CA3121270A CA3121270A1 CA 3121270 A1 CA3121270 A1 CA 3121270A1 CA 3121270 A CA3121270 A CA 3121270A CA 3121270 A CA3121270 A CA 3121270A CA 3121270 A1 CA3121270 A1 CA 3121270A1
Authority
CA
Canada
Prior art keywords
talabostat
treatment
pembrolizumab
months
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121270A
Other languages
English (en)
French (fr)
Inventor
Vincent J. O'NEILL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of CA3121270A1 publication Critical patent/CA3121270A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3121270A 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation Pending CA3121270A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US62/777,352 2018-12-10
US201962924429P 2019-10-22 2019-10-22
US62/924,429 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
CA3121270A1 true CA3121270A1 (en) 2020-06-18

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121270A Pending CA3121270A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Country Status (13)

Country Link
US (1) US20220089733A1 (https=)
EP (1) EP3893869A4 (https=)
JP (2) JP2022512158A (https=)
KR (1) KR20210102259A (https=)
CN (1) CN113260361A (https=)
AU (1) AU2019396206A1 (https=)
BR (1) BR112021011205A2 (https=)
CA (1) CA3121270A1 (https=)
IL (1) IL283742A (https=)
MX (1) MX2021006778A (https=)
SG (1) SG11202106129RA (https=)
TW (1) TW202034955A (https=)
WO (1) WO2020123496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2021158884A1 (en) * 2020-02-07 2021-08-12 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2973040A1 (en) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US11613785B2 (en) * 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
JP2025156353A (ja) 2025-10-14
KR20210102259A (ko) 2021-08-19
EP3893869A1 (en) 2021-10-20
TW202034955A (zh) 2020-10-01
JP2022512158A (ja) 2022-02-02
WO2020123496A1 (en) 2020-06-18
CN113260361A (zh) 2021-08-13
BR112021011205A2 (pt) 2021-08-24
EP3893869A4 (en) 2022-08-17
SG11202106129RA (en) 2021-07-29
IL283742A (en) 2021-07-29
MX2021006778A (es) 2021-07-15
US20220089733A1 (en) 2022-03-24
AU2019396206A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
JP2024545125A (ja) Ｓｔａｔ３分解剤およびその使用
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
KR20230086660A (ko) 통풍의 치료 방법
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
TW202346335A (zh) 治療al類澱粉變性症之方法
WO2023136837A1 (en) Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc)
US20220257759A1 (en) Treatment of sarcoma using immunomodulation
US20240307397A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Siu Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
TW202513098A (zh) 治療癌症之方法
TW202547553A (zh) 治療ａｌ類澱粉變性症之方法
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
Johnson Phase II Study of Durvalumab (MEDI4736)(anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer.
Phaëton et al. SPONSOR SIGNATURE PAGE
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
Gonçalves et al. CLINICAL STUDY AUTHORISATION FOR PROTOCOL N 0101/1709
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
Redmond Protocol Number: PHS IRB: 15-166

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919